VRDN·Viridian Therapeutics, Inc.
VRDN|Analyst Targets
VRDN|Insider Trading
VRDN|Fundamentals
VRDN|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $-0.72 | - | - |
| Q3'26 | $-0.99 | $-0.81 | +18.0% |
| Q3'25 | $-0.94 | $-0.34 | +63.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $49M | - | - |
| Q3'26 | - | $26M | - |
| Q3'25 | - | $71M | - |
VRDN|Monthly Returns
Market Data
VRDN Stock Snapshot
- Market cap
- 3.35B
- Day range
- $29.81 – $30.96
- News sentiment
- 71/100 · Bullish
- Analyst target
- $42.19 (+36.7%)
- Consensus
- Buy · 25 analysts
Momentum has rolled over on Viridian Therapeutics, Inc., which is what drives the bearish read. Thinner liquidity means moves can extend past what the fundamentals alone justify.
Behaviour On Record
What VRDN's own history says about today's numbers
- Realized volatility (21d)
- 97.5% 75th pct
- Below its peak
- -98.5%
- vs 200-day average
- +40.7%
- Up days (1y)
- 48%
Viridian Therapeutics, Inc. is currently running 97.5% annualised volatility over the last 21 sessions. Measured against VRDN's own 11 years of daily returns rather than a market-wide average, that is the 75th percentile — elevated for this stock, against a typical reading of 71.5%.
VRDN is trading -98.5% below its running peak. Across 10 full years on file, its median worst-drawdown-in-a-year was -71.6%, and the deepest was -90.9% in 2019. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.
Price sits +40.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 91st percentile — a wider gap than this stock usually carries. Over the past year VRDN closed higher on 48% of sessions, and it is currently 3 sessions into a falling streak.
On November specifically: over 12 years of records, VRDN finished the month higher 8 of 12 times, with a median return of +16.8% and an average of +12.8%. Its strongest month historically has been January at +19.5% on average, its weakest February at -14.5%.
Overnight risk is measurable too: VRDN has opened more than 2% away from the prior close in 775 of 2,804 sessions (27.6% of the time), with the largest gaps running +57.5% and -39.2%.
All figures computed from 2,808 daily closes between 2014-06-18 and 2026-11-13, split-adjusted, recomputed daily. Percentiles are against VRDN's own 12-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of VRDN's sector?
Viridian Therapeutics, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, VRDN ranks 9th of 15 tracked industries, weakening.
- Sector rank
- #2 of 12
- Sector state
- Weakening
- Sector rotation score
- 82
- Industry rank
- #9 of 15
Analyst Consensus Estimates
What do analysts expect VRDN to earn?
Analysts expect Viridian Therapeutics, Inc. to earn -$3.92 per share in the fiscal year ending Dec 2026 and $2.00 in the fiscal year ending Dec 2029, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Analyst Rating Changes
Are analysts turning bullish or bearish on VRDN?
Wedbush most recently reiterated its rating on Viridian Therapeutics, Inc. to Outperform on Nov 10, 2026 with a price target of $44 (from $42). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Wedbush: Outperform
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Corporate Stakes
Which companies own a stake in VRDN?
Merck & Co., Inc. reports a stake in Viridian Therapeutics, Inc. on SEC Form 13F: 93.4K shares, about 0.09% of the company, worth $1.9M at the end of Q3 2026. At today's price that stake is worth $2.9M, about 0.00% of MRK's own market value.
- Holder
- MRK
- Shares held
- 93.4K
- Stake
- 0.09%
- Value
- $1.9M
Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.
Earnings Release, Scored
What did Viridian Therapeutics, Inc.'s latest earnings release say?
Most important lines
- 1
R&D Expenses: Research and development expenses were $70.1 million during the three months ended September 30, 2026, compared to $86.3 million during the three months ended September 30, 2025.
- 2
In non-human primates, a single, high-dose of VRDN-008 showed a longer half-life and more sustained IgG reduction versus efgartigimod in a head-to-head study.
- 3
Net Loss: Net loss for the three months ended September 30, 2026 was $101.2 million, compared with $34.6 million for the same period in 2025.
Negative tone
ETF holders
ETFs holding VRDN
Top ETF holdersWeight
News & sentiment
What is the news saying about VRDN?
VRDN rose 65.0% over the month to Nov 13. News tone held between 50 and 100 from Oct 16 to Nov 2, then dropped to 16 on Nov 3.
- Oct 23 -11.9%
- Oct 26 +15.5%
- Nov 4 +18.2%same day: Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
Technical analysis
How strong is VRDN's momentum right now?
On the daily chart VRDN ranks at the 10th percentile for momentum against 1,062 stocks and ETFs, a bearish reading.
Institutional ownership
Are big funds buying or selling VRDN?
33 of the 59 tracked managers added to VRDN in their latest 13F and 22 trimmed. Together they own 48.9% of the company, worth $1.1B. Fidelity and BlackRock alone hold 24.7%.
- 1FMR LLC (Fidelity)16.12%$360.5M positionAdded 43.2% last quarter
- 2BlackRock, Inc.8.59%$192.1M positionNew position last quarter
- 3State Street Corp4.49%$100.4M positionTrimmed 20.4% last quarter
- $97.9M positionAdded 3.9% last quarter
- $57.7M positionNew position last quarter
- $49.8M positionTrimmed 12.2% last quarter
- $36.1M positionAdded 8.8% last quarter
- 8Candriam S.C.A.1.41%$31.6M positionTrimmed 10.6% last quarter
- $20.0M positionTrimmed 12.5% last quarter
- 10Morgan Stanley0.74%$16.6M positionNew position last quarter
Discover more
How has VRDN done against its peers?
Over the six months to Nov 13, VRDN returned +72.5%. Of the 15 related stocks and ETFs, 1 did better, led by MRNA at +345.8%.
- 1MRNAModerna, Inc.up 345.8%+273.3 pts
- 2VRDNThis stockup 72.5%
- 3ARKGARK Genomic Revolution ETFup 44.7%−27.7 pts
- 4AMGNAmgen Inc.up 38.4%−34.1 pts
- 5ROIVRoivant Sciences Ltd.up 35.8%−36.6 pts
- 6REGNRegeneron Pharmaceuticals, Inc.up 33.0%−39.4 pts
- 7RPRXRoyalty Pharma plcup 29.4%−43.0 pts
- 8XLVHealth Care Select Sector SPDR Fundup 28.7%−43.8 pts
- 16UTHRUnited Therapeutics Corporationup 2.0%−70.5 pts